{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:27:43Z","timestamp":1789802863942,"version":"4.0.1"},"reference-count":91,"publisher":"Portland Press Ltd.","issue":"12","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:p>In Crohn's disease, one of the two major forms of inflammatory bowel diseases in human beings, persistent and chronic inflammation promotes fibrotic processes thereby facilitating formation of strictures, the most common indication for surgical intervention in this disorder. The pathogenesis of Crohn's disease-associated fibrosis is not fully understood, but variants of genes involved in the recognition of microbial components\/products [e.g. CARD15 (caspase-activating recruitment domain 15) and ATG16L1 (autophagy-related 16-like 1)] are associated with this phenotype, and experimental evidence suggests that intestinal fibrosis results from an altered balance between deposition of ECM (extracellular matrix) and degradation of ECM by proteases. Studies have also contributed to identify the main phenotypic and functional alterations of cells involved in the fibrogenic process, as well as molecules that stimulate such cells to produce elevated amounts of collagen and other ECM-related proteins. In the present review, we assess the current knowledge about cellular and molecular mediators of intestinal fibrosis and describe results of recent studies aimed at testing the preventive\/therapeutic effect of compounds in experimental models of intestinal fibrosis.<\/jats:p>","DOI":"10.1042\/cs20150472","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T01:38:37Z","timestamp":1445564317000},"page":"1107-1113","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease"],"prefix":"10.1042","volume":"129","author":[{"given":"Francesca","family":"Zorzi","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"2021113010552691400_B1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn's disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm. Bowel Dis."},{"key":"2021113010552691400_B2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1572-0241.2006.01010.x","article-title":"Fibrogenesis in Crohn's disease","volume":"102","author":"Burke","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"2021113010552691400_B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00054725-200401000-00009","article-title":"Medical therapy for Crohn's disease strictures","volume":"10","author":"Van Assche","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"2021113010552691400_B4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/gut.33.3.331","article-title":"Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms","volume":"33","author":"Olaison","year":"1992","journal-title":"Gut"},{"key":"2021113010552691400_B5","doi-asserted-by":"publisher","first-page":"G786","DOI":"10.1152\/ajpgi.00059.2012","article-title":"Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease","volume":"303","author":"Rieder","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"2021113010552691400_B7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/gast.2002.32413","article-title":"The molecular classification of the clinical manifestations of Crohn's disease","volume":"122","author":"Ahmad","year":"2002","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B8","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/gutjnl-2011-300777","article-title":"Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project","volume":"62","author":"Cleynen","year":"2013","journal-title":"Gut"},{"key":"2021113010552691400_B9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1086\/339432","article-title":"CARD15\/NOD2 mutational analysis and genotype\u2013phenotype correlation in 612 patients with inflammatory bowel disease","volume":"70","author":"Lesage","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"2021113010552691400_B10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1053\/gast.2002.35393","article-title":"Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease","volume":"123","author":"Abreu","year":"2002","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.sla.0000186173.14696.ea","article-title":"Crohn's disease patients carrying Nod2\/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence","volume":"242","author":"Alvarez-Lobos","year":"2005","journal-title":"Ann. Surg."},{"key":"2021113010552691400_B12","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1074\/jbc.M008072200","article-title":"Nod2, a Nod1\/Apaf-1 family member that is restricted to monocytes and activates NF-\u03baB","volume":"276","author":"Ogura","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021113010552691400_B13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.coi.2008.06.001","article-title":"NOD-like receptors (NLRs): bona fide intracellular microbial sensors","volume":"20","author":"Shaw","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"2021113010552691400_B14","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1074\/jbc.C200651200","article-title":"Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection","volume":"278","author":"Girardin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021113010552691400_B15","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/j.1572-0241.2004.40304.x","article-title":"Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis","volume":"99","author":"Economou","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"2021113010552691400_B16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1053\/gast.2002.32415","article-title":"The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease","volume":"122","author":"Cuthbert","year":"2002","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35079114","article-title":"A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease","volume":"411","author":"Ogura","year":"2001","journal-title":"Nature"},{"key":"2021113010552691400_B18","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1053\/j.gastro.2010.07.006","article-title":"ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis","volume":"139","author":"Homer","year":"2010","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ni.1823","article-title":"Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry","volume":"11","author":"Travassos","year":"2010","journal-title":"Nat. Immunol."},{"key":"2021113010552691400_B20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.dld.2014.02.016","article-title":"Autophagy genes variants and paediatric Crohn's disease phenotype: a single-centre experience","volume":"46","author":"Strisciuglio","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"2021113010552691400_B21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1111\/j.1572-0241.2008.02023.x","article-title":"ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity","volume":"103","author":"Fowler","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"2021113010552691400_B22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.1103685","article-title":"Nod2 mutation in Crohn's disease potentiates NF-\u03baB activity and IL-1\u03b2 processing","volume":"307","author":"Maeda","year":"2005","journal-title":"Science"},{"key":"2021113010552691400_B23","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/MEG.0b013e3282f824c9","article-title":"The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease","volume":"20","author":"Sabate","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"2021113010552691400_B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1572-0241.2005.00361.x","article-title":"Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype","volume":"101","author":"Brand","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"2021113010552691400_B25","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1136\/jmg.2005.040477","article-title":"Angiotensinogen and transforming growth factor \u03b21: novel genes in the pathogenesis of Crohn's disease","volume":"43","author":"Hume","year":"2006","journal-title":"J. Med. Genet."},{"key":"2021113010552691400_B26","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.3748\/wjg.v13.i21.2960","article-title":"Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-\u03b1 single nucleotide gene polymorphisms in inflammatory bowel disease","volume":"13","author":"Meijer","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"2021113010552691400_B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.09.008","article-title":"Cellular and molecular mediators of intestinal fibrosis","author":"Lawrance","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"2021113010552691400_B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"2021113010552691400_B29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor mono-clonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.crohns.2008.05.009","article-title":"Current knowledge and future perspectives","volume":"2","author":"Rieder","year":"2008","journal-title":"J. Crohns Colitis"},{"key":"2021113010552691400_B31","doi-asserted-by":"publisher","first-page":"G677","DOI":"10.1152\/ajpgi.00104.2011","article-title":"Themes in fibrosis and gastrointestinal inflammation","volume":"300","author":"Fiocchi","year":"2011","journal-title":"Am. J. Physiol."},{"key":"2021113010552691400_B32","doi-asserted-by":"crossref","first-page":"G1307","DOI":"10.1152\/ajpgi.2000.279.6.G1307","article-title":"IGF-I and procollagen \u03b11(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease","volume":"279","author":"Pucilowska","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B33","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/0016-5085(92)90314-O","article-title":"Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease","volume":"102","author":"Stallmach","year":"1992","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0016-5085(88)90411-8","article-title":"Collagen content and types in the intestinal strictures of Crohn's disease","volume":"94","author":"Graham","year":"1998","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0889-8553(05)70061-3","article-title":"Surgical therapy for ulcerative colitis and Crohn's disease","volume":"28","author":"Becker","year":"1999","journal-title":"Gastroenterol. Clin. North Am."},{"key":"2021113010552691400_B36","doi-asserted-by":"crossref","first-page":"G653","DOI":"10.1152\/ajpgi.2000.279.4.G653","article-title":"Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models","volume":"279","author":"Pucilowska","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0016-5085(92)90087-F","article-title":"Cellular localization of procollagen gene transcripts in inflammatory bowel diseases","volume":"102","author":"Matthes","year":"1992","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1046\/j.1365-2249.2000.01227.x","article-title":"Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease","volume":"120","author":"Louis","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"2021113010552691400_B39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/gut.47.1.57","article-title":"Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesion of children with inflammatory bowel disease","volume":"47","author":"Heuschkel","year":"2000","journal-title":"Gut"},{"key":"2021113010552691400_B40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry","volume":"92","author":"Visse","year":"2003","journal-title":"Circ. Res."},{"key":"2021113010552691400_B41","doi-asserted-by":"publisher","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","article-title":"Matrix metalloproteinases","volume":"274","author":"Nagase","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021113010552691400_B42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.dld.2005.02.011","article-title":"Expression of matrix metalloproteinases-2 and 9 in intestinal tissue of patients with inflammatory bowel diseases","volume":"37","author":"Gao","year":"2005","journal-title":"Dig. Liver Dis."},{"key":"2021113010552691400_B43","first-page":"111","article-title":"Tissue inhibitors of metalloproteinases: structure, regulation and biological functions","volume":"74","author":"Gomez","year":"1997","journal-title":"Eur. J. Cell Biol."},{"key":"2021113010552691400_B44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0167-4838(99)00279-4","article-title":"Tissue inhibitors of metalloproteinases: evolution, structure and function","volume":"1477","author":"Brew","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113010552691400_B45","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S0002-9440(10)63931-4","article-title":"Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease","volume":"162","author":"McKaig","year":"2003","journal-title":"Am. J. Pathol."},{"key":"2021113010552691400_B46","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2003.08.027","article-title":"A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-\u03baB","volume":"125","author":"Lawrance","year":"2003","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrgastro.2009.31","article-title":"Intestinal fibrosis in IBD: a dynamic, multifactorial process","volume":"6","author":"Rieder","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2021113010552691400_B48","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-\u03b2 signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"key":"2021113010552691400_B49","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.3748\/wjg.v18.i28.3635","article-title":"Cellular and molecular mechanisms of intestinal fibrosis","volume":"18","author":"Speca","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"2021113010552691400_B50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"2021113010552691400_B51","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0016-5085(03)00403-7","article-title":"Intestinal myofibroblasts in innate immune responses of the intestine","volume":"124","author":"Otte","year":"2003","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2249.2007.03531.x","article-title":"Increased expression of Toll-like receptor (TLR) 2 TLR4 in the colonic mucosa of children with inflammatory bowel disease","volume":"151","author":"Szebeni","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"2021113010552691400_B53","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1172\/JCI30595","article-title":"Infectious disease, the immune response and fibrosis","volume":"117","author":"Meneghin","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2021113010552691400_B54","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.cytogfr.2005.03.004","article-title":"Chemokines provide the sustained inflammatory bridge between innate and acquired immunity","volume":"16","author":"Coelho","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"2021113010552691400_B55","doi-asserted-by":"publisher","first-page":"C172","DOI":"10.1152\/ajpcell.00048.2001","article-title":"Differential expression of TGF-\u03b2 isoforms by normal and inflammatory bowel disease intestinal myofibroblasts","volume":"282","author":"McKaig","year":"2002","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113010552691400_B56","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","article-title":"TGF-\u03b2 signaling and the fibrotic response","volume":"18","author":"Leask","year":"2004","journal-title":"FASEB J"},{"key":"2021113010552691400_B57","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/gut.2008.149096","article-title":"Transforming growth factor \u03b2 signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures","volume":"58","author":"Di Sabatino","year":"2009","journal-title":"Gut"},{"key":"2021113010552691400_B58","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/01.sla.0000189606.58343.cd","article-title":"Transforming growth factor-\u03b2 promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1\/2 mitogen activated protein kinase cell signaling","volume":"242","author":"Mulsow","year":"2005","journal-title":"Ann. Surg."},{"key":"2021113010552691400_B59","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0898-6568(02)00058-X","article-title":"Integration of the TGF-\u03b2 pathway into the cellular signalling network","volume":"14","author":"Lutz","year":"2002","journal-title":"Cell. Signal."},{"key":"2021113010552691400_B60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.it.2004.07.008","article-title":"Smad7 in TGF-\u03b2-mediated negative regulation of gut inflammation","volume":"25","author":"Monteleone","year":"2004","journal-title":"Trends Immunol"},{"key":"2021113010552691400_B61","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1101\/gad.12.11.1587","article-title":"Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases","volume":"12","author":"de Caestecker","year":"1998","journal-title":"Genes Dev."},{"key":"2021113010552691400_B62","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1074\/jbc.274.13.8797","article-title":"MEKK-1, a component of the stress (stress-activated protein kinase\/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells","volume":"274","author":"Brown","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021113010552691400_B63","doi-asserted-by":"publisher","first-page":"28858","DOI":"10.1074\/jbc.M910358199","article-title":"c-Jun inhibits transforming growth factor \u03b2-mediated transcription by repressing Smad3 transcriptional activity","volume":"275","author":"Dennler","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021113010552691400_B64","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.0022-202X.2005.23750.x","article-title":"Smad3 and extracellular signal-regulated kinase 1\/2 coordinately mediate transforming growth factor-\u03b2-induced expression of connective tissue growth factor in human fibroblasts","volume":"124","author":"Leivonen","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"2021113010552691400_B65","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1096\/fj.03-0037fje","article-title":"Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-\u03b2-dependent responses in human mesangial cells","volume":"17","author":"Hayashida","year":"2003","journal-title":"FASEB J"},{"key":"2021113010552691400_B66","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021113010552691400_B67","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"key":"2021113010552691400_B68","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/apt.12051","article-title":"A phase 1 open-label trial shows that Smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease","volume":"36","author":"Zorzi","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2021113010552691400_B69","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1172\/JCI1876","article-title":"Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation","volume":"101","author":"Jobson","year":"1998","journal-title":"J. Clin. Invest."},{"key":"2021113010552691400_B70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0016-5085(97)70176-8","article-title":"Autocrine regulation of growth in cultured human intestinal muscle by growth factors","volume":"113","author":"Kuemmerle","year":"1997","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B71","doi-asserted-by":"crossref","first-page":"G809","DOI":"10.1152\/ajpgi.00057.2002","article-title":"IGF-I and TGF-\u03b21 have distinct effects on phenotype and proliferation of intestinal fibroblasts","volume":"283","author":"Simmons","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B72","doi-asserted-by":"publisher","first-page":"G101","DOI":"10.1152\/ajpgi.00032.2004","article-title":"Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3 \u03b2 activity","volume":"288","author":"Kuemmerle","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B73","doi-asserted-by":"publisher","first-page":"G411","DOI":"10.1152\/ajpgi.00310.2002","article-title":"IGF-I elicits growth of human intestinal smooth muscle cells by activation of PI3K, PDK-1, and p70S6 kinase","volume":"284","author":"Kuemmerle","year":"2003","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B74","first-page":"G151","article-title":"IGF-I stimulates intestinal muscle cell growth by activating distinct PI 3-kinase and MAP kinase pathways","volume":"275","author":"Kuemmerle","year":"1998","journal-title":"Am. J. Physiol."},{"key":"2021113010552691400_B75","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1053\/j.gastro.2009.09.003","article-title":"Endogenous IGF-I and \u03b1V\u03b23 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease","volume":"138","author":"Flynn","year":"2010","journal-title":"Gastroenterology"},{"key":"2021113010552691400_B76","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/MIB.0000000000000043","article-title":"Mechanisms that mediate the development of fibrosis in patients with Crohn's disease","volume":"20","author":"Li","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"2021113010552691400_B77","doi-asserted-by":"publisher","first-page":"G326","DOI":"10.1152\/ajpgi.00083.2011","article-title":"Resveratrol causes cell cycle arrest, decreased collagen synthesis, and apoptosis in rat intestinal smooth muscle cells","volume":"302","author":"Garcia","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113010552691400_B78","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.3748\/wjg.v20.i16.4648","article-title":"Resveratrol inhibits collagen I synthesis by suppressing IGF-1R activation in intestinal fibroblasts","volume":"20","author":"Li","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"2021113010552691400_B79","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ibd.21843","article-title":"Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan\u2013polysaccharide rat model of Crohn's disease","volume":"18","author":"Rahal","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"2021113010552691400_B80","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2353\/ajpath.2010.090923","article-title":"Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3","volume":"177","author":"Li","year":"2010","journal-title":"Am. J. Pathol."},{"key":"2021113010552691400_B81","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/mi.2014.35","article-title":"Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut","volume":"7","author":"Caruso","year":"2014","journal-title":"Mucosal Immunol"},{"key":"2021113010552691400_B82","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MIB.0b013e3182a8452e","article-title":"Increased activation of latent TGF\u03b21 by \u03b1V\u03b23 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide","volume":"144","author":"Li","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"2021113010552691400_B83","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin\u2013angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol. Rev."},{"key":"2021113010552691400_B84","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s10620-006-9124-2","article-title":"Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition","volume":"52","author":"Spencer","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"2021113010552691400_B85","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s10495-005-2138-y","article-title":"Intestinal intraepithelial lymphocyte derived angiotensin converting enzyme modulates epithelial cell apoptosis","volume":"10","author":"Wildhaber","year":"2005","journal-title":"Apoptosis"},{"key":"2021113010552691400_B86","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/002215540205000215","article-title":"Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa","volume":"50","author":"Hirasawa","year":"2002","journal-title":"J. Histochem. Cytochem."},{"key":"2021113010552691400_B87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.surg.2008.03.043","article-title":"Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse model: development of a unique mode of treatment","volume":"144","author":"Koga","year":"2008","journal-title":"Surgery"},{"key":"2021113010552691400_B88","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00054725-200409000-00007","article-title":"Prevention of fibrosis in experimental colitis by captopril: the role of TGF-\u03b21","volume":"10","author":"Wengrower","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"2021113010552691400_B89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.regpep.2005.03.009","article-title":"The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats","volume":"130","author":"Jahovic","year":"2005","journal-title":"Regul. Pept."},{"key":"2021113010552691400_B90","doi-asserted-by":"publisher","first-page":"e5263","DOI":"10.1371\/journal.pone.0005263","article-title":"Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease","volume":"4","author":"Grip","year":"2009","journal-title":"PLoS One"},{"key":"2021113010552691400_B91","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/bjp.2008.369","article-title":"Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease","volume":"155","author":"Grip","year":"2008","journal-title":"Br. J. Pharmacol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/129\/12\/1107\/448331\/cs1291107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/129\/12\/1107\/448331\/cs1291107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:47:15Z","timestamp":1638272835000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/129\/12\/1107\/71743\/Pathogenic-aspects-and-therapeutic-avenues-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20150472","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]}}}